Premium
Report from the International Union Against Cancer (UICC) Tumor Biology Committee
Author(s) -
Salgaller Michael L.,
Thurnher Martin,
Bartsch Georg,
Boynton Alton L.,
Murphy Gerald P.
Publication year - 1999
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19991215)86:12<2674::aid-cncr12>3.0.co;2-z
Subject(s) - medicine , action (physics) , institution , cancer , political science , law , physics , quantum mechanics
At this workshop, clinicians active in the use of dendritic cells all expressed the need to have an available supply of interleukin (IL)‐4. There was discussion that unless some institution, such as the National Cancer Institute of the U.S., took action, a stable commercial source of IL‐4 might not be available in the future. The UICC leadership is currently looking into this matter. See also pages 2593–6.